Switch to:
Also traded in: Chile, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.66
GILD's Cash to Debt is ranked lower than
85% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. GILD: 0.66 )
Ranked among companies with meaningful Cash to Debt only.
GILD' s Cash to Debt Range Over the Past 10 Years
Min: 0.23  Med: 1.44 Max: 3021.78
Current: 0.66
0.23
3021.78
Equity to Asset 0.36
GILD's Equity to Asset is ranked lower than
81% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GILD: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
GILD' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.58 Max: 0.94
Current: 0.36
0.36
0.94
Interest Coverage 32.26
GILD's Interest Coverage is ranked lower than
72% of the 393 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 32.26 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 36.36 Max: 221.35
Current: 32.26
11.11
221.35
F-Score: 5
Z-Score: 5.36
M-Score: -2.45
WACC vs ROIC
11.32%
87.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 68.00
GILD's Operating margin (%) is ranked higher than
98% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. GILD: 68.00 )
Ranked among companies with meaningful Operating margin (%) only.
GILD' s Operating margin (%) Range Over the Past 10 Years
Min: -25.07  Med: 50.02 Max: 68
Current: 68
-25.07
68
Net-margin (%) 55.48
GILD's Net-margin (%) is ranked higher than
96% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. GILD: 55.48 )
Ranked among companies with meaningful Net-margin (%) only.
GILD' s Net-margin (%) Range Over the Past 10 Years
Min: -39.32  Med: 37.05 Max: 55.48
Current: 55.48
-39.32
55.48
ROE (%) 106.72
GILD's ROE (%) is ranked higher than
99% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. GILD: 106.72 )
Ranked among companies with meaningful ROE (%) only.
GILD' s ROE (%) Range Over the Past 10 Years
Min: -49.14  Med: 48.50 Max: 106.64
Current: 106.72
-49.14
106.64
ROA (%) 42.18
GILD's ROA (%) is ranked higher than
98% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. GILD: 42.18 )
Ranked among companies with meaningful ROA (%) only.
GILD' s ROA (%) Range Over the Past 10 Years
Min: -30.31  Med: 29.37 Max: 42.28
Current: 42.18
-30.31
42.28
ROC (Joel Greenblatt) (%) 650.72
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. GILD: 650.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GILD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -71.55  Med: 176.02 Max: 595.44
Current: 650.72
-71.55
595.44
Revenue Growth (3Y)(%) 51.80
GILD's Revenue Growth (3Y)(%) is ranked higher than
90% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. GILD: 51.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GILD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 13.2  Med: 45.10 Max: 70.4
Current: 51.8
13.2
70.4
EBITDA Growth (3Y)(%) 76.20
GILD's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. GILD: 76.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GILD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.3  Med: 37.70 Max: 116.7
Current: 76.2
-16.3
116.7
EPS Growth (3Y)(%) 93.70
GILD's EPS Growth (3Y)(%) is ranked higher than
97% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. GILD: 93.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GILD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 30.80 Max: 143.3
Current: 93.7
0
143.3
» GILD's 10-Y Financials

Financials (Next Earnings Date: 2016-04-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

GILD Guru Trades in Q2 2015

John Hussman 75,000 sh (New)
Westport Asset Management 95,000 sh (New)
Ray Dalio 81,721 sh (+224.02%)
Julian Robertson 399,411 sh (+72.52%)
David Dreman 9,525 sh (+70.70%)
Paul Tudor Jones 10,380 sh (+58.84%)
NWQ Managers 145,200 sh (+28.38%)
John Buckingham 57,343 sh (+26.64%)
John Rogers 1,106,494 sh (+24.10%)
Pioneer Investments 3,274,401 sh (+7.47%)
Murray Stahl 8,950 sh (+2.87%)
Ken Fisher 791,630 sh (+0.26%)
Dodge & Cox 4,250 sh (unchged)
First Eagle Investment 400 sh (unchged)
Steven Cohen Sold Out
Ronald Muhlenkamp 218,620 sh (-0.05%)
Joel Greenblatt 1,068,128 sh (-3.58%)
Mario Gabelli 43,925 sh (-11.21%)
Lee Ainslie 2,340 sh (-11.70%)
RS Investment Management 125,840 sh (-13.11%)
Jeremy Grantham 3,600 sh (-21.74%)
Louis Moore Bacon 19,142 sh (-56.88%)
Jim Simons 1,310,100 sh (-67.51%)
John Burbank 2,295 sh (-94.97%)
» More
Q3 2015

GILD Guru Trades in Q3 2015

John Keeley 29,029 sh (New)
John Burbank 29,586 sh (+1189.15%)
Ray Dalio 222,121 sh (+171.80%)
RS Investment Management 156,503 sh (+24.37%)
John Rogers 1,313,500 sh (+18.71%)
David Dreman 11,228 sh (+17.88%)
NWQ Managers 169,500 sh (+16.74%)
Murray Stahl 9,950 sh (+11.17%)
John Buckingham 61,912 sh (+7.97%)
Pioneer Investments 3,283,529 sh (+0.28%)
Jeremy Grantham 3,600 sh (unchged)
David Carlson 550,000 sh (unchged)
Dodge & Cox 4,250 sh (unchged)
First Eagle Investment 400 sh (unchged)
Lee Ainslie 2,340 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
John Hussman 75,000 sh (unchged)
Louis Moore Bacon Sold Out
Ronald Muhlenkamp 217,990 sh (-0.29%)
Mario Gabelli 43,750 sh (-0.40%)
Julian Robertson 352,311 sh (-11.79%)
Joel Greenblatt 936,982 sh (-12.28%)
Ken Fisher 562,391 sh (-28.96%)
Paul Tudor Jones 7,300 sh (-29.67%)
Jim Simons 280,300 sh (-78.60%)
» More
Q4 2015

GILD Guru Trades in Q4 2015

Louis Moore Bacon 20,493 sh (New)
Diamond Hill Capital 2,070 sh (New)
Jeff Auxier 2,282 sh (New)
T Rowe Price Equity Income Fund 1,250,000 sh (New)
Jim Simons 2,319,448 sh (+727.49%)
Paul Tudor Jones 16,614 sh (+127.59%)
Julian Robertson 394,411 sh (+11.95%)
Pioneer Investments 3,392,997 sh (+3.33%)
John Buckingham 63,796 sh (+3.04%)
Murray Stahl 10,000 sh (+0.50%)
Ken Fisher 563,917 sh (+0.27%)
Lee Ainslie 2,340 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
John Rogers 1,313,500 sh (unchged)
David Carlson 550,000 sh (unchged)
First Eagle Investment 400 sh (unchged)
Jeremy Grantham 3,600 sh (unchged)
Samuel Isaly 327,100 sh (unchged)
John Keeley Sold Out
John Hussman Sold Out
John Burbank Sold Out
David Dreman Sold Out
Ronald Muhlenkamp 217,975 sh (-0.01%)
RS Investment Management 155,231 sh (-0.81%)
NWQ Managers 166,900 sh (-1.53%)
Ray Dalio 218,121 sh (-1.80%)
Mario Gabelli 42,700 sh (-2.40%)
Joel Greenblatt 874,246 sh (-6.70%)
Dodge & Cox 3,750 sh (-11.76%)
» More
Q1 2016

GILD Guru Trades in Q1 2016

T Rowe Price Equity Income Fund 1,353,600 sh (+8.29%)
Murray Stahl 10,000 sh (unchged)
Samuel Isaly 327,100 sh (unchged)
Ken Fisher 487,030 sh (-13.63%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Gilead Sciences Inc

John Rogers Comments on Gilead Sciences Inc. - Dec 02, 2015

Biotechnology leader Gilead Sciences, Inc. (NASDAQ:GILD) dropped -15.90% on recent concerns over drug pricing. Gilead actually reported quarterly earnings that were better than expected. We continue to hold the shares, based on our belief that the market is overly focused on pricing and underestimating future sales that we think are likely to grow.





From John Rogers (Trades, Portfolio) 3rd quarter commentary on the Ariel Global Fund.

Check out John Rogers latest stock trades

Top Ranked Articles about Gilead Sciences Inc

Gilead, Fossil Among Stocks Trading Below Lynch Earnings Line Using Peter Lynch's valuation method to find investment ideas
Former Magellan fund manager Peter Lynch devised a method of determining whether stocks are over or undervalued by equating $1 in earnings with $15 in stock price. The earnings line was introduced in his best-selling book “One Up on Wall Street.” Read more...
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Recent insider sells from company CEOs
According to GuruFocus Insider Data, these are the largest CEO sells during the past week: Gilead Sciences Inc., Boston Scientific Corp., Sonic Corp. and HealthEquity Inc. Read more...
A Look Back at 2 Successful Biotech Buyouts Pharmasset and Idenix were both acquired at huge premiums
The biotech pharmaceutical business is all about clinical trials, FDA approvals and the potential market its addresses. Most of the biotech companies experienced rising stock market prices despite the fact that it had consistently generated negative earnings over time. The negative earnings were due to the high R&D expenses it occurred during the testing and clinical trials phase. Normally, those biotech companies would be acquired by larger, established pharmaceutical firms at a huge premium to its stock price. They got acquired not because of their earnings they have generated in the past, but because of the current drug pipelines, which could create a lot of cash flow in the future. Read more...
The Best Reason to Love Gilead's Market Correction The transition from a growth to value stock is creating a compelling opportunity
When successful high-growth businesses are eventually confronted with making the transition from a growth business model to a value business model, the momentum traders who have previously held positions tend to dump shares and move on. The selling typically causes a substantial drop in share price. Read more...
Ackman, Sequoia Stock Valeant Changes Course Controversial pharma company Valeant is making changes but some shorts still don't see the value
A pharmaceutical company fueling most of its rapid growth through acquisitions, Valeant (NYSE:VRX) responded to a short-seller’s accusations this week by announcing a change of business model at its 2015 Investor Day. Read more...
Gurus Add to Stakes in Biopharmaceutical Research Company Ray Dalio and Pioneer Investments buy shares of Gilead Sciences
Guru Ray Dalio (Trades, Portfolio) added 140,400 shares of Gilead Sciences Inc. (NASDAQ:GILD), a research-based biopharmaceutical company that discovers, develops and markets innovative medicines, to his portfolio in the third quarter. Read more...
John Rogers Comments on Gilead Sciences Inc. Guru stock highlight
Biotechnology leader Gilead Sciences, Inc. (NASDAQ:GILD) dropped -15.90% on recent concerns over drug pricing. Gilead actually reported quarterly earnings that were better than expected. We continue to hold the shares, based on our belief that the market is overly focused on pricing and underestimating future sales that we think are likely to grow. Read more...
Weekly CFO Sells Highlight: Gilead Sciences, Axalta Coating Systems, and Facebook A roundup of recent insider sales from CFOs
According to GuruFocus Insider Data, the recent CFO sales were: Gilead Sciences Inc. (NASDAQ:GILD), Axalta Coating Systems Ltd. (NYSE:AXTA), and Facebook Inc. (NASDAQ:FB). Read more...
Weekly CFO Sells Highlight: Adobe Systems, Gilead Sciences and Alphabet Insiders sell company shares
According to GuruFocus Insider Data, the recent CFO sales were: Adobe Systems Inc. (NASDAQ:ADBE), Gilead Sciences Inc. (NASDAQ:GILD) and Alphabet Inc. (NASDAQ:GOOG). Read more...
Weekly Insider Sells Highlight: Flowers Foods, Gilead Sciences, Cigna, HanesBrands A summary of the largest insider sells in the last week
According to GuruFocus Insider Data, the largest insider sells during the past week were: Flowers Foods Inc. (NYSE:FLO), Gilead Sciences Inc. (NASDAQ:GILD), Cigna Corp. (NYSE:CI) and HanesBrands Inc. (NYSE:HBI). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 8.43
GILD's P/E(ttm) is ranked higher than
87% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 30.50 vs. GILD: 8.43 )
Ranked among companies with meaningful P/E(ttm) only.
GILD' s P/E(ttm) Range Over the Past 10 Years
Min: 6.96  Med: 19.78 Max: 45.41
Current: 8.43
6.96
45.41
Forward P/E 8.14
GILD's Forward P/E is ranked higher than
83% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 17.92 vs. GILD: 8.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 8.43
GILD's PE(NRI) is ranked higher than
88% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. GILD: 8.43 )
Ranked among companies with meaningful PE(NRI) only.
GILD' s PE(NRI) Range Over the Past 10 Years
Min: 6.96  Med: 19.78 Max: 45.49
Current: 8.43
6.96
45.49
Price/Owner Earnings (ttm) 7.65
GILD's Price/Owner Earnings (ttm) is ranked higher than
87% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 33.75 vs. GILD: 7.65 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GILD' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.31  Med: 19.08 Max: 74.51
Current: 7.65
6.31
74.51
P/B 7.72
GILD's P/B is ranked lower than
78% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. GILD: 7.72 )
Ranked among companies with meaningful P/B only.
GILD' s P/B Range Over the Past 10 Years
Min: 4.15  Med: 8.34 Max: 18.71
Current: 7.72
4.15
18.71
P/S 4.72
GILD's P/S is ranked higher than
72% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. GILD: 4.72 )
Ranked among companies with meaningful P/S only.
GILD' s P/S Range Over the Past 10 Years
Min: 3.53  Med: 7.76 Max: 14.38
Current: 4.72
3.53
14.38
PFCF 7.89
GILD's PFCF is ranked higher than
88% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 30.93 vs. GILD: 7.89 )
Ranked among companies with meaningful PFCF only.
GILD' s PFCF Range Over the Past 10 Years
Min: 6.51  Med: 21.49 Max: 57.83
Current: 7.89
6.51
57.83
POCF 7.60
GILD's POCF is ranked higher than
85% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 25.07 vs. GILD: 7.60 )
Ranked among companies with meaningful POCF only.
GILD' s POCF Range Over the Past 10 Years
Min: 6.27  Med: 19.32 Max: 51.28
Current: 7.6
6.27
51.28
EV-to-EBIT 6.51
GILD's EV-to-EBIT is ranked higher than
79% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.70 vs. GILD: 6.51 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.2  Med: 14.10 Max: 209.2
Current: 6.51
-154.2
209.2
EV-to-EBITDA 6.26
GILD's EV-to-EBITDA is ranked higher than
80% of the 275 Companies
in the Global Biotechnology industry.

( Industry Median: 20.64 vs. GILD: 6.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.9  Med: 13.30 Max: 168
Current: 6.26
-189.9
168
PEG 0.19
GILD's PEG is ranked higher than
95% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. GILD: 0.19 )
Ranked among companies with meaningful PEG only.
GILD' s PEG Range Over the Past 10 Years
Min: 0.14  Med: 0.93 Max: 3.75
Current: 0.19
0.14
3.75
Shiller P/E 34.19
GILD's Shiller P/E is ranked higher than
73% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.88 vs. GILD: 34.19 )
Ranked among companies with meaningful Shiller P/E only.
GILD' s Shiller P/E Range Over the Past 10 Years
Min: 26.54  Med: 60.08 Max: 2078
Current: 34.19
26.54
2078
Current Ratio 2.50
GILD's Current Ratio is ranked lower than
70% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. GILD: 2.50 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 6.09 Max: 18.65
Current: 2.5
1.09
18.65
Quick Ratio 2.31
GILD's Quick Ratio is ranked lower than
68% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GILD: 2.31 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 5.58 Max: 18.65
Current: 2.31
0.83
18.65
Days Inventory 169.03
GILD's Days Inventory is ranked lower than
65% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 120.79 vs. GILD: 169.03 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 148.53  Med: 224.63 Max: 328.95
Current: 169.03
148.53
328.95
Days Sales Outstanding 65.46
GILD's Days Sales Outstanding is ranked higher than
51% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. GILD: 65.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.46  Med: 70.56 Max: 84.93
Current: 65.46
65.46
84.93
Days Payable 107.33
GILD's Days Payable is ranked higher than
67% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 63.23 vs. GILD: 107.33 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 92.02  Med: 172.90 Max: 309.16
Current: 107.33
92.02
309.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.72
GILD's Dividend Yield is ranked higher than
70% of the 208 Companies
in the Global Biotechnology industry.

( Industry Median: 1.34 vs. GILD: 1.72 )
Ranked among companies with meaningful Dividend Yield only.
GILD' s Dividend Yield Range Over the Past 10 Years
Min: 0.36  Med: 0.86 Max: 1.55
Current: 1.72
0.36
1.55
Dividend Payout 0.11
GILD's Dividend Payout is ranked higher than
90% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.33 vs. GILD: 0.11 )
Ranked among companies with meaningful Dividend Payout only.
GILD' s Dividend Payout Range Over the Past 10 Years
Min: 0.11  Med: 0.11 Max: 0.11
Current: 0.11
Forward Dividend Yield 1.71
GILD's Forward Dividend Yield is ranked higher than
69% of the 190 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. GILD: 1.71 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.70
GILD's Yield on cost (5-Year) is ranked higher than
58% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. GILD: 1.70 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GILD' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.36  Med: 0.85 Max: 1.7
Current: 1.7
0.36
1.7
3-Year Average Share Buyback Ratio 1.30
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. GILD: 1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.5  Med: -1.40 Max: 6.2
Current: 1.3
-18.5
6.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.13
GILD's Price/Tangible Book is ranked lower than
89% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. GILD: 20.13 )
Ranked among companies with meaningful Price/Tangible Book only.
GILD' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.46  Med: 9.76 Max: 44.42
Current: 20.13
2.46
44.42
Price/Projected FCF 1.24
GILD's Price/Projected FCF is ranked higher than
84% of the 172 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. GILD: 1.24 )
Ranked among companies with meaningful Price/Projected FCF only.
GILD' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.81  Med: 2.50 Max: 20.25
Current: 1.24
0.81
20.25
Price/Median PS Value 0.61
GILD's Price/Median PS Value is ranked higher than
76% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. GILD: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
GILD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 1.41 Max: 3.54
Current: 0.61
0.5
3.54
Price/Peter Lynch Fair Value 0.34
GILD's Price/Peter Lynch Fair Value is ranked higher than
93% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 1.87 vs. GILD: 0.34 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GILD' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.34  Med: 1.00 Max: 9.13
Current: 0.34
0.34
9.13
Price/Graham Number 2.75
GILD's Price/Graham Number is ranked lower than
54% of the 292 Companies
in the Global Biotechnology industry.

( Industry Median: 2.51 vs. GILD: 2.75 )
Ranked among companies with meaningful Price/Graham Number only.
GILD' s Price/Graham Number Range Over the Past 10 Years
Min: 1.78  Med: 3.48 Max: 9.13
Current: 2.75
1.78
9.13
Earnings Yield (Greenblatt) (%) 15.35
GILD's Earnings Yield (Greenblatt) (%) is ranked higher than
94% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. GILD: 15.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GILD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 6.80 Max: 16.6
Current: 15.35
0.5
16.6
Forward Rate of Return (Yacktman) (%) 54.08
GILD's Forward Rate of Return (Yacktman) (%) is ranked higher than
95% of the 107 Companies
in the Global Biotechnology industry.

( Industry Median: 14.45 vs. GILD: 54.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GILD' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.7  Med: 5.80 Max: 55.2
Current: 54.08
0.7
55.2

More Statistics

Revenue(Mil) $32639
EPS $ 11.93
Beta1.39
Short Percentage of Float1.97%
52-Week Range $81.89 - 123.37
Shares Outstanding(Mil)1366.85

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 31,348 30,689 30,141
EPS($) 12.23 12.37 12.88
EPS without NRI($) 12.23 12.37 12.88

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:GILD.Chile, GIS.Germany, GILD.Mexico, GILD.Switzerland,
Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors
» More Articles for NAS:GILD

Headlines

Articles On GuruFocus.com
Gilead, Fossil Among Stocks Trading Below Lynch Earnings Line Apr 13 2016 
Take 5: Consider Stocking Up on Gilead Sciences Apr 12 2016 
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Apr 10 2016 
Finding the Best Stocks to Invest In Mar 31 2016 
An Attempt to Value Valeant Just for Fun Mar 23 2016 
Gilead Sciences’ Miracle Drug Combination Mar 22 2016 
Gilead, Expedia Are Largely Undervalued Mar 17 2016 
Weekly CEO Sells Highlight: Motorcar Parts of America, The Interpublic Group of Companies, Gilead Sc Mar 07 2016 
A Look Back at 2 Successful Biotech Buyouts Feb 21 2016 
Valeant and Gilead's Growth Were Not Created Equal Feb 21 2016 

More From Other Websites
Gilead Sciences (GILD) Stock Retreats Ahead of Q1 Results Despite Credit Suisse's Optimism Apr 28 2016
Will Gilead’s Run Come to an End this Quarter? Apr 28 2016
Gilead Sciences Inc Earnings Call scheduled for 4:30 pm ET today Apr 28 2016
Q1 2016 Gilead Sciences Inc Earnings Release - After Market Close Apr 28 2016
Amazon Earnings Top 5 Things You Need To Know For Thursday Apr 27 2016
Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News Apr 27 2016
Credit Suisse Ups Gilead Target Ahead Of Earnings Apr 27 2016
Street Talk: LB, GILD, BLMN, & more Apr 27 2016
Why Gilead Should Gain On Q1 Earnings Apr 27 2016
4 Biotech Stocks Reporting on Apr 28: AMGN, GILD, ALXN, CELG Apr 27 2016
Why Gilead Sciences (GILD) Might Surprise This Earnings Season Apr 27 2016
Short Sellers Run for Cover From Major Biotechs Apr 27 2016
Gilead Sciences Shows Further Upside Potential Apr 26 2016
Biotech Stock Gilead (GILD) Likely to Beat in Q1 Earnings Apr 26 2016
Big Biotech In The Earnings Spotlight Apr 26 2016
DMG MORI confirms annual forecast for 2016 Business development according to plan in the first... Apr 26 2016
These Are The Companies Reporting Earnings This Week Apr 25 2016
Healthcare Q1 Earnings Look Solid: ETFs to Benefit Apr 25 2016
5 Stocks to Watch this Week 4/25 - AAPL, CMG, FB, AMZN, GILD Apr 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK